Adicet Bio Diluted EPS
The Diluted Earnings per Share of Adicet Bio (ACET) as of Aug 22, 2026 is -16.95 USD. In the previous year, Diluted Earnings per Share was -21.33 USD — a change of -20.53% (higher).
Get this data via API
Financial Data API
Diluted EPS
-16.95USD
YoY
-20.53%
Last updated:
The Adicet Bio Diluted EPS history
3 Years
10 Years
25 Years
Max
| YEAR | Diluted EPS | YoY |
|---|---|---|
| -16.95USD | -20.53% | |
| -21.33USD | -59.79% | |
| -53.04USD | +97.84% | |
| -26.81USD | -8.35% | |
| -29.25USD | -2.21% | |
| -29.91USD | +23.30% | |
| -24.26USD | +6,797.39% | |
| -0.35USD | -58.25% | |
| -0.84USD | +138,861.65% | |
| -0.00USD | -100.00% | |
| 17.98USD | +28.55% | |
| 13.99USD | — |
Adicet Bio Stock analysis
Frequently Asked Questions about Adicet Bio stock
Diluted Earnings per Share of Adicet Bio is -16.95 USD in 2026.
Diluted Earnings per Share of Adicet Bio changed from -21.33 USD to -16.95 USD, representing a -20.53% change. The value is higher than the previous year.
On Eulerpool you can find the complete historical development of Diluted Earnings per Share Adicet Bio since 2006 – with annual values, charts, and detailed analysis.
Diluted EPS accounts for all potential shares from options, warrants, and convertible securities. It provides a more conservative per-share earnings measure.
Income Statement — Adicet Bio
All Key Metrics — Adicet Bio
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth